Clinical, histological and molecular follow-up of 60 patients with gastric marginal zone lymphoma of mucosa-associated lymphoid tissue.
The persistence of gastric lymphoma after Helicobacter pylori eradication may be difficult to evidence on endoscopic and histological examination. The aims of the study were to evaluate the detection of monoclonal immunoglobulin H (IgH) gene rearrangement in endoscopically infiltrated and normal mucosa at diagnosis and during follow-up in order to determine its clinical and prognostic impact. We studied 60 gastric marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT), and IgH monoclonality was detected at diagnosis in 52 patients (87%). The endoscopically normal mucosa contained clonal lymphomatous cells in 69% of cases before remission. A complete histological remission (HR) was observed in 28 patients (47%). Among them, 23 were followed for molecular remission (MR). The median delay was 10 months to achieve HR and 18 months to achieve MR. Interestingly, patients with HR but not MR had a longer delay to achieve HR (21 months) (P=0.0006) and a more frequent clonal normal mucosa at diagnosis (88%) than patients with both HR and MR (10 months and 39%, respectively). The presence of monoclonal B cells at both infiltrated and normal sites may therefore identify patients with a longer delay to achieve complete response, suggesting that molecular dissemination may require therapeutic intensification.
de Mascarel
Antoine
A
Department of Pathology, University Victor Segalen Bordeaux 2, Hôpital Haut-Lévêque, 33604 Pessac cedex, France. antoine.demascarel@chu-bordeaux.fr
Ruskone-Fourmestraux
Agnès
A
Lavergne-Slove
Anne
A
Megraud
Francis
F
Dubus
Pierre
P
Merlio
Jean-Philippe
JP
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000658:Amoxicillin / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005753:Gastric Mucosa / Q000276:immunology / Q000473:pathology; D015321:Gene Rearrangement / Q000276:immunology*; D016481:Helicobacter Infections / Q000188:drug therapy; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics*; D064747:Lansoprazole; D018442:Lymphoma, B-Cell, Marginal Zone / Q000235:genetics* / Q000276:immunology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016133:Polymerase Chain Reaction; D011379:Prognosis; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000235:genetics* / Q000276:immunology* / Q000473:pathology
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000890:Anti-Infective Agents; D007143:Immunoglobulin Heavy Chains; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole
Lancet. 1995 Jun 24;345(8965):1591-4
7783535
Lancet. 1993 Sep 4;342(8871):568
8102714
Recent Results Cancer Res. 2000;156:116-24
10802871
Haematologica. 2001 Jun;86(6):609-17
11418369
Lancet. 1991 Nov 9;338(8776):1175-6
1682595
Mod Pathol. 2001 Oct;14(10):957-62
11598164
Blood. 1996 Feb 15;87(4):1255-60
8608213
Strahlentherapie. 1977 Apr;153(4):218-21
857349
J Pathol. 2000 Dec;192(4):488-93
11113866
Gastroenterology. 2000 Nov;119(5):1191-202
11054376
Blood. 2002 Apr 1;99(7):2541-4
11895791
J Clin Oncol. 2001 Mar 15;19(6):1600-9
11250988
Lancet. 1993 Sep 4;342(8871):575-7
8102719
Hum Pathol. 1994 Oct;25(10):1020-9
7927306
J Natl Cancer Inst. 1997 Sep 17;89(18):1350-5
9308704
Histopathology. 1999 Apr;34(4):326-30
10231400
Hum Pathol. 1998 Aug;29(8):784-90
9712418
Am J Gastroenterol. 1998 May;93(5):732-6
9625118
Ann Intern Med. 1995 May 15;122(10):767-9
7717599
Ann Intern Med. 1999 Jul 20;131(2):88-95
10419446
Gut. 2001 Mar;48(3):297-303
11171816